68 results
6-K
EX-99.1
CLYYF
Celyad Oncology SA
21 Nov 23
Current report (foreign)
8:06am
measures
The Company will grant access to the meeting room only to the extent permitted by the authorities on the meeting’s date. The Company
6-K
EX-99.1
CLYYF
Celyad Oncology SA
27 Oct 23
Current report (foreign)
1:45pm
, but only with a consultation right.
PARTICIPATION IN THE MEETING
Covid-19 measures
The Company will grant access to the meeting room only
6-K
EX-99.1
CLYYF
Celyad Oncology SA
22 Sep 23
Current report (foreign)
6:06am
right.
PARTICIPATION IN THE MEETING
Covid-19 measures
The Company will grant access to the meeting room only to the extent permitted by the authorities
6-K
EX-99.1
CLYYF
Celyad Oncology SA
5 Sep 23
Celyad Oncology Reports First Half 2023 Financial
6:12am
recent changes and upcoming milestones.
Participants may access the conference call by dialing +1-877-407-9716 or +1-201-493-6779 (United States … , International), +32 (0) 800-73-904 (Belgium Fixed) or +32 (0) 800-73-566 (Belgium Mobile). Participants may ask for instant telephone access to the event
6-K
EX-99.2
CLYYF
Celyad Oncology SA
5 Sep 23
Celyad Oncology Reports First Half 2023 Financial
6:12am
.
The development of allogeneic,‘off-the-shelf’
CART-
cells allows to overcome many of these limitations, contributing to scalability and direct access to CART
6-K
EX-10.3
dxalc7f
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
6-K
EX-10.4
3plg wlikz6de9m883
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
6-K
EX-10.2
q8bl3 1l4lzgc0mms8v
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
6-K
EX-10.1
b8s646djotzuhz
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
6-K
EX-99.1
844hdhhitw66h
4 Apr 23
Current report (foreign)
7:45am
6-K
EX-99.1
952w7r5ms4armg6n6gz
5 Aug 22
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights
6:11am
6-K
EX-99.2
kn9jtu
5 Aug 22
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights
6:11am
6-K
EX-99.1
gdp19rlq
6 May 22
Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
5:23pm
6-K
EX-99.1
pocxq9s
24 Mar 22
Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
5:45pm
6-K
EX-99.1
ef6gkd3qsqsejn7m8
12 Jan 22
Celyad Oncology Provides Outlook for 2022
6:06am
6-K
EX-10.2
2zzv9pz
3 Dec 21
Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group
9:19am
6-K
cbli e8p6x
3 Dec 21
Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group
9:19am
6-K
EX-10.1
ex3uvt dwr38vr2nehc
3 Dec 21
Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group
9:19am
6-K
EX-99.1
q4i51
3 Dec 21
Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group
9:19am